Cargando…
Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe
BACKGROUND: Paediatric atopic dermatitis (AD) can be burdensome, affecting mental health and impairing quality of life for children and caregivers. Comprehensive guidelines exist for managing paediatric AD, but practical guidance on using systemic therapy is limited, particularly for new therapies i...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796032/ https://www.ncbi.nlm.nih.gov/pubmed/35793471 http://dx.doi.org/10.1111/jdv.18410 |
_version_ | 1784860390262308864 |
---|---|
author | de Graaf, M. Janmohamed, S.R. Schuttelaar, M.L.A. Agner, T. Alfonso, J.H. De Schepper, S. Deleuran, M. Despontin, K. Elenius, V. Ghislain, P.‐D. Huilaja, L. Johansson, E.K. Kvenshagen, B.K. Mandelin, J.M. Olset, H. Svensson, A. van Tuyll van Serooskerken, A.M. Thyssen, J.P. Vestergaard, C. |
author_facet | de Graaf, M. Janmohamed, S.R. Schuttelaar, M.L.A. Agner, T. Alfonso, J.H. De Schepper, S. Deleuran, M. Despontin, K. Elenius, V. Ghislain, P.‐D. Huilaja, L. Johansson, E.K. Kvenshagen, B.K. Mandelin, J.M. Olset, H. Svensson, A. van Tuyll van Serooskerken, A.M. Thyssen, J.P. Vestergaard, C. |
author_sort | de Graaf, M. |
collection | PubMed |
description | BACKGROUND: Paediatric atopic dermatitis (AD) can be burdensome, affecting mental health and impairing quality of life for children and caregivers. Comprehensive guidelines exist for managing paediatric AD, but practical guidance on using systemic therapy is limited, particularly for new therapies including biologics and Janus kinase (JAK) inhibitors, recently approved for various ages in this indication. OBJECTIVES: This expert consensus aimed to provide practical recommendations within this advancing field to enhance clinical decision‐making on the use of these and other systemics for children and adolescents aged ≥2 years with moderate‐to‐severe AD. METHODS: Nineteen physicians from Northern Europe were selected for their expertise in managing childhood AD. Using a two‐round Delphi process, they reached full or partial consensus on 37 statements. RESULTS: Systemic therapy is recommended for children aged ≥2 years with a clear clinical diagnosis of severe AD and persistent disease uncontrolled after optimizing non‐systemic therapy. Systemic therapy should achieve long‐term disease control and reduce short‐term interventions. Recommended are cyclosporine A for short‐term use (all ages) and dupilumab or methotrexate for long‐term use (ages ≥6 years). Consensus was not reached on the best long‐term systemics for children aged 2–6 years, although new systemic therapies will likely become favourable: New biologics and JAK inhibitors will soon be approved for this age group, and more trial and real‐world data will become available. CONCLUSIONS: This article makes practical recommendations on the use of systemic AD treatments for children and adolescents, to supplement international and regional guidelines. It considers the systemic medication that was available for children and adolescents with moderate‐to‐severe AD at the time this consensus project was done: azathioprine, cyclosporine A, dupilumab, methotrexate, mycophenolate mofetil and oral glucocorticosteroids. We focus on the geographically similar Northern European countries, whose healthcare systems, local preferences for AD management and reimbursement structures nonetheless differ significantly. |
format | Online Article Text |
id | pubmed-9796032 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97960322022-12-28 Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe de Graaf, M. Janmohamed, S.R. Schuttelaar, M.L.A. Agner, T. Alfonso, J.H. De Schepper, S. Deleuran, M. Despontin, K. Elenius, V. Ghislain, P.‐D. Huilaja, L. Johansson, E.K. Kvenshagen, B.K. Mandelin, J.M. Olset, H. Svensson, A. van Tuyll van Serooskerken, A.M. Thyssen, J.P. Vestergaard, C. J Eur Acad Dermatol Venereol Original Articles and Short Reports BACKGROUND: Paediatric atopic dermatitis (AD) can be burdensome, affecting mental health and impairing quality of life for children and caregivers. Comprehensive guidelines exist for managing paediatric AD, but practical guidance on using systemic therapy is limited, particularly for new therapies including biologics and Janus kinase (JAK) inhibitors, recently approved for various ages in this indication. OBJECTIVES: This expert consensus aimed to provide practical recommendations within this advancing field to enhance clinical decision‐making on the use of these and other systemics for children and adolescents aged ≥2 years with moderate‐to‐severe AD. METHODS: Nineteen physicians from Northern Europe were selected for their expertise in managing childhood AD. Using a two‐round Delphi process, they reached full or partial consensus on 37 statements. RESULTS: Systemic therapy is recommended for children aged ≥2 years with a clear clinical diagnosis of severe AD and persistent disease uncontrolled after optimizing non‐systemic therapy. Systemic therapy should achieve long‐term disease control and reduce short‐term interventions. Recommended are cyclosporine A for short‐term use (all ages) and dupilumab or methotrexate for long‐term use (ages ≥6 years). Consensus was not reached on the best long‐term systemics for children aged 2–6 years, although new systemic therapies will likely become favourable: New biologics and JAK inhibitors will soon be approved for this age group, and more trial and real‐world data will become available. CONCLUSIONS: This article makes practical recommendations on the use of systemic AD treatments for children and adolescents, to supplement international and regional guidelines. It considers the systemic medication that was available for children and adolescents with moderate‐to‐severe AD at the time this consensus project was done: azathioprine, cyclosporine A, dupilumab, methotrexate, mycophenolate mofetil and oral glucocorticosteroids. We focus on the geographically similar Northern European countries, whose healthcare systems, local preferences for AD management and reimbursement structures nonetheless differ significantly. John Wiley and Sons Inc. 2022-07-19 2022-11 /pmc/articles/PMC9796032/ /pubmed/35793471 http://dx.doi.org/10.1111/jdv.18410 Text en © 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles and Short Reports de Graaf, M. Janmohamed, S.R. Schuttelaar, M.L.A. Agner, T. Alfonso, J.H. De Schepper, S. Deleuran, M. Despontin, K. Elenius, V. Ghislain, P.‐D. Huilaja, L. Johansson, E.K. Kvenshagen, B.K. Mandelin, J.M. Olset, H. Svensson, A. van Tuyll van Serooskerken, A.M. Thyssen, J.P. Vestergaard, C. Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe |
title | Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe |
title_full | Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe |
title_fullStr | Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe |
title_full_unstemmed | Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe |
title_short | Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe |
title_sort | systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a delphi consensus project mapping expert opinion in northern europe |
topic | Original Articles and Short Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796032/ https://www.ncbi.nlm.nih.gov/pubmed/35793471 http://dx.doi.org/10.1111/jdv.18410 |
work_keys_str_mv | AT degraafm systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT janmohamedsr systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT schuttelaarmla systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT agnert systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT alfonsojh systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT descheppers systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT deleuranm systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT despontink systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT eleniusv systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT ghislainpd systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT huilajal systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT johanssonek systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT kvenshagenbk systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT mandelinjm systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT olseth systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT svenssona systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT vantuyllvanserooskerkenam systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT thyssenjp systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope AT vestergaardc systemictreatmentofchildrenandadolescentswithatopicdermatitisaged2yearsadelphiconsensusprojectmappingexpertopinioninnortherneurope |